ClinicalTrials.gg
CompletedNCT05994807Updated Oct 19, 2026Results posted

A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants

A Phase 1 interventional study of DC-806 and Itraconazole in Healthy Volunteers, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science

Updated Oct 19, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary objective of this study was to assess the effect of a cytochrome P450 3A4 (CYP3A4) inhibitor (itraconazole) and CYP3A4 inducer (carbamazepine) on the single dose pharmacokinetics (PK) of DC-806 coadministered with itraconazole or carbamazepine in healthy male and female participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • DC-806
  • Drug-Drug Interaction
  • Itraconazole
  • Carbamazepine
03

In context

Lead sponsor

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company is the lead sponsor of 10 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 4 (40%) have results posted.

First submitted the day DICE Therapeutics, Inc. became part of Eli Lilly and Company.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sex : male or female; females must be of non-, or .
  2. Age : 18 to 55 years, inclusive, at screening.
  3. (BMI) : 18.0 to 32.0 kg/m\^2, inclusive, at screening.
  4. Weight : ≥50 kg, inclusive, at screening.
  5. Status : healthy participants. Healthy status as defined by the absence of evidence of any , in the opinion of the investigator, active, or chronic disease.
  6. Male participants and female participants of childbearing potential must agree to use protocol specified methods of and comply with pregnancy precautions as described in the protocol.
  7. All prescribed medication must have been stopped at least 14 days prior to admission to the clinical site.
  8. All over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (e.g., St. John's wort) must have been stopped at least 7 days (or 5 half-lives for certain medications, whichever is longer) prior to admission to the clinical site. Occasional use of acetaminophen/paracetamol (e.g., up to 2 grams per day) is permitted during this period and throughout the study.
  9. Ability and willingness to abstain from alcohol-, caffeine-, and methylxanthine-containing beverages or food (e.g., coffee, tea, cola, chocolate, energy drinks) from 48 hours (2 days) prior to admission to the clinical site and during confinement at the clinical site.
  10. Willingness to abstain from any strenuous physical exercise from 96 hours (4 days) prior to admission and during confinement at the clinical site.
  11. Good physical and mental health on the basis of medical history, physical examination, clinical laboratory assessments, 12-lead (ECG), Columbia-Suicide Severity Rating Scale (C-SSRS) (Cohort 2 only) and vital signs, as judged by the Investigator.
  12. Willing and able to sign the form (ICF).

Exclusion criteria

Exclusion Criteria:

  1. Employee of ICON or the Sponsor.
  2. History of relevant drug and/or food allergies, in the opinion of the Investigator.
  3. Females who are currently breastfeeding.
  4. Smoking more than 5 cigarettes, 1 cigar, or 1 pipe daily within 3 months prior to screening.
  5. Unwilling or unable to abstain from tobacco products within the 48 hours (2 days) prior to admission and during confinement at the clinical site.
  6. History of alcohol abuse or drug addiction (including soft drugs like cannabis products) within 1 year prior to screening.
  7. Positive drug and/or alcohol screen (opiates, methadone, cocaine, amphetamines [including ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants, and alcohol) at screening or admission to the clinical site.
  8. History within the previous 12 months of alcohol consumption exceeding 2 standard drinks per day on average. Alcohol consumption will be prohibited 48 hours prior to admission to the clinical facility and until discharge in the study period.
  9. Positive screen for surface antigen, virus (HCV) antibodies, or (HIV) 1 and 2 antibodies.
  10. Consumption of any nutrients known to modulate cytochrome P450 (CYP450) enzymes activity (e.g., grapefruit or grapefruit juice, pomelo juice, star fruit, or Seville [blood] orange products) within 14 days prior to the first administration of study drug and during the study (including /clinic furlough until after discharge in the last study period).
  11. Participation in a drug study within 30 days prior to study drug administration in the current study. Participation in 4 or more other drug studies in the 12 months prior to study drug administration in the current study.
  12. History of donation of more than 450 mL of blood within 60 days prior to dosing in the clinical site or planned donation before 30 days has elapsed since intake of study drug.
  13. Plasma or donation within 7 days of dosing and through follow-up.
  14. Significant and/or acute illness within 5 days prior to study drug administration that may impact safety assessments, in the opinion of the Investigator.
  15. Unsuitable veins for infusion or blood sampling as determined by the Investigator or study staff.
  16. Any other condition or prior therapy that, in the Investigator's opinion, would confound or interfere with the evaluation of safety, tolerability, or pharmacokinetics (PK) of the study drug, interfere with study compliance, or preclude .

    Cohort 2 Only:

  17. Individuals who have Asian ancestry (including those who have one or more Asian grandparents).
  18. Presence of active suicidal ideation or positive suicide behavior using the "Baseline/Screening" version of the C-SSRS and with either of the following criteria:

    • History of a suicide attempt within the 5 years prior to the Screening Visit. Participants with a history of a suicide attempt more than 5 years ago should be evaluated by a mental healthcare professional (e.g., locally licensed psychiatrist, psychologist, or master's level therapist) before enrolling into the study.
    • Suicidal ideation in the past month prior to the Screening Visit as indicated by a positive response ("Yes") to either Question 4 or 5 of the "Baseline/Screening" version of the C-SSRS.
  19. History of epilepsy.
  20. Leukopenia (white blood cell count \<lower limit of normal [LLN]), neutropenia ( \<LLN), or thrombocytopenia (platelet count \<LLN), at screening or admission (Day -1).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Cohort 1 (DC-806 200 mg / Itraconazole)

    Participants received: Period 1: A single oral dose of 200 milligram (mg) DC-806 under fasted conditions on Day 1. Period 2: Multiple oral doses of 200 mg itraconazole once daily (QD) under fed conditions on Days 4 to 6. Period 3: Day 7: A single oral dose of 200 mg DC-806 was administered 2 hours after a single oral dose of 200 mg itraconazole under fasted conditions, in the morning on Day 7. Day 8 to Day 10: QD dosing of itraconazole 200 mg was continued until Day 10 under fed conditions.

    Drug: DC-806 · Drug: Itraconazole

  • Experimental
    Cohort 2 (DC-806 800 mg / Carbamazepine)

    Participants received: Period 1: A single oral dose of 800 mg DC-806 on Day 1 under fasted conditions. Period 2: Multiple ascending oral doses of twice daily (BID) carbamazepine, under fed conditions, as follows: Day 4 to Day 5: BID doses of 100 mg carbamazepine. Day 6 to Day 7: BID doses of 200 mg carbamazepine. Day 8 to Day 17: BID doses of 300 mg carbamazepine. Period 3: Day 18, morning dosing: a single oral dose of 800 mg DC-806 was coadministered with 300 mg carbamazepine under fasted conditions. Day 18, Evening dosing: a single oral dose of 300 mg carbamazepine were administered under fed conditions. Day 19 to Day 20: BID administration of 300 mg carbamazepine was continued until Day 20, under fed conditions. Day 21 to Day 22: BID doses of 200 mg carbamazepine, under fed conditions. Day 23 to Day 24: BID doses of 100 mg carbamazepine, under fed conditions.

    Drug: DC-806 · Drug: Carbamazepine

Interventions

06

What researchers measure

Primary outcomes

  1. Cohort 1: Maximum Observed Plasma Concentration (Cmax) of DC-806

    Cmax of DC-806 alone on Day 1 and when coadministered with itraconazole on Day 7.

    Time frame: Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 7 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)

  2. Cohort 1: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of DC-806

    AUC0-t of DC-806 alone on Day 1 and when coadministered with itraconazole on Day 7.

    Time frame: Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 7 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)

  3. Cohort 1: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of DC-806

    AUC0-inf of DC-806 alone on Day 1 and when coadministered with itraconazole on Day 7.

    Time frame: Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 7 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)

  4. Cohort 2: Maximum Observed Plasma Concentration (Cmax) of DC-806

    Cmax of DC-806 alone on Day 1 and when coadministered with carbamazepine on Day 18.

    Time frame: Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 18 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)

  5. Cohort 2: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of DC-806

    AUC0-t of DC-806 alone on Day 1 and when coadministered with carbamazepine on Day 18.

    Time frame: Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 18 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)

  6. Cohort 2: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of DC-806

    AUC0-inf of DC-806 alone on Day 1 and when coadministered with carbamazepine on Day 18.

    Time frame: Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 18 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    A TEAE was defined as any adverse event that began on or after the first dose of study drug or began before the first dose of study drug and worsened on or after the first dose of study drug.

    Time frame: Cohort 1: Day 1 up to Day 23; Cohort 2: Day 1 up to Day 33.

07

Results

Posted Oct 19, 2026

Participant flow

Participants were enrolled into two cohorts, with each cohort having 3 treatment periods. * Cohort 1: Period 1 (Days 1 to 3), Period 2 (Days 4 to 6), Period 3 (Days 7 to 10). * Cohort 2: Period 1 (Days 1 to 3), Period 2 (Days 4 to 17), Period 3 (Days 18 to 25).

Participant flow — Overall Study
MilestoneCohort 1 (DC-806 200 mg / Itraconazole)Cohort 2 (DC-806 800 mg / Carbamazepine)
Started1716
Safety analyses set1716
Completed1514
Not completed22
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up10
Withdrew: Adverse event02

Outcome measures

PrimaryCohort 1: Maximum Observed Plasma Concentration (Cmax) of DC-806

Cmax of DC-806 alone on Day 1 and when coadministered with itraconazole on Day 7.

Time frame:
Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 7 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Cohort 1: Maximum Observed Plasma Concentration (Cmax) of DC-806
nanograms per milliliter (ng/mL)Cohort 1 (DC-806 200 mg / Itraconazole)
Day 1383 ± 53.6
Day 71490 ± 46.3
PrimaryCohort 1: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of DC-806

AUC0-t of DC-806 alone on Day 1 and when coadministered with itraconazole on Day 7.

Time frame:
Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 7 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
Reported as:
Geometric mean · hour*nanograms per milliliter (h*ng/mL)
Cohort 1: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of DC-806
hour*nanograms per milliliter (h*ng/mL)Cohort 1 (DC-806 200 mg / Itraconazole)
Day 1983 ± 49.6
Day 76640 ± 48.6
PrimaryCohort 1: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of DC-806

AUC0-inf of DC-806 alone on Day 1 and when coadministered with itraconazole on Day 7.

Time frame:
Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 7 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
Reported as:
Geometric mean · hour*nanograms per milliliter (h*ng/mL)
Cohort 1: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of DC-806
hour*nanograms per milliliter (h*ng/mL)Cohort 1 (DC-806 200 mg / Itraconazole)
Day 11000 ± 48.9
Day 76970 ± 46.5
PrimaryCohort 2: Maximum Observed Plasma Concentration (Cmax) of DC-806

Cmax of DC-806 alone on Day 1 and when coadministered with carbamazepine on Day 18.

Time frame:
Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 18 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Cohort 2: Maximum Observed Plasma Concentration (Cmax) of DC-806
nanograms per milliliter (ng/mL)Cohort 2 (DC-806 800 mg / Carbamazepine)
Day 12740 ± 40.5
Day 181100 ± 34.6
PrimaryCohort 2: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of DC-806

AUC0-t of DC-806 alone on Day 1 and when coadministered with carbamazepine on Day 18.

Time frame:
Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 18 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
Reported as:
Geometric mean · hour*nanograms per milliliter (h*ng/mL)
Cohort 2: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of DC-806
hour*nanograms per milliliter (h*ng/mL)Cohort 2 (DC-806 800 mg / Carbamazepine)
Day 17720 ± 31.0
Day 182850 ± 21.8
PrimaryCohort 2: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of DC-806

AUC0-inf of DC-806 alone on Day 1 and when coadministered with carbamazepine on Day 18.

Time frame:
Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 18 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
Reported as:
Geometric mean · hour*nanograms per milliliter (h*ng/mL)
Cohort 2: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of DC-806
hour*nanograms per milliliter (h*ng/mL)Cohort 2 (DC-806 800 mg / Carbamazepine)
Day 18000 ± 29.5
Day 182870 ± 21.7
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

A TEAE was defined as any adverse event that began on or after the first dose of study drug or began before the first dose of study drug and worsened on or after the first dose of study drug.

Time frame:
Cohort 1: Day 1 up to Day 23; Cohort 2: Day 1 up to Day 33.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsCohort 1: DC-806 200 mg (Days 1 to 3)Cohort 1: Itraconazole (Days 4 to 6)Cohort 1: DC-806 200 mg + Itraconazole (From Day 7)Cohort 1: Overall (DC-806 200 mg / Itraconazole)Cohort 2: DC-806 800 mg (Days 1 to 3)Cohort 2: Carbamazepine (Days 4 to 17)Cohort 2: DC-806 800 mg + Carbamazepine (From Day 18)Cohort 2: Overall (DC-806 800 mg / Carbamazepine)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)100128210

Adverse events

Collected over Cohort 1: Day 1 up to Day 23; Cohort 2: Day 1 up to Day 33.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: DC-806 200 mg (Days 1 to 3)0/17 (0%)0/17 (0%)1/17 (5.9%)
Cohort 1: Itraconazole (Days 4 to 6)0/16 (0%)0/16 (0%)0/16 (0%)
Cohort 1: DC-806 200 mg + Itraconazole (From Day 7)0/16 (0%)0/16 (0%)0/16 (0%)
Cohort 1: Overall (DC-806 200 mg / Itraconazole)0/17 (0%)0/17 (0%)1/17 (5.9%)
Cohort 2: DC-806 800 mg (Days 1 to 3)0/16 (0%)0/16 (0%)2/16 (12.5%)
Cohort 2: Carbamazepine (Days 4 to 17)0/16 (0%)0/16 (0%)8/16 (50%)
Cohort 2: DC-806 800 mg + Carbamazepine (From Day 18)0/14 (0%)0/14 (0%)2/14 (14.3%)
Cohort 2: Overall (DC-806 800 mg / Carbamazepine)0/16 (0%)0/16 (0%)10/16 (62.5%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventCohort 1: DC-806 200 mg (Days 1 to 3)Cohort 1: Itraconazole (Days 4 to 6)Cohort 1: DC-806 200 mg + Itraconazole (From Day 7)Cohort 1: Overall (DC-806 200 mg / Itraconazole)Cohort 2: DC-806 800 mg (Days 1 to 3)Cohort 2: Carbamazepine (Days 4 to 17)Cohort 2: DC-806 800 mg + Carbamazepine (From Day 18)Cohort 2: Overall (DC-806 800 mg / Carbamazepine)
HeadacheNervous system disorders0/170/160/160/171/164/161/146/16
DizzinessNervous system disorders0/170/160/160/170/163/160/143/16
ConstipationGastrointestinal disorders0/170/160/160/170/162/160/142/16
EructationGastrointestinal disorders0/170/160/160/170/160/161/141/16
DysgeusiaNervous system disorders0/170/160/160/170/160/161/141/16
ThrombocytopeniaBlood and lymphatic system disorders0/170/160/160/170/161/160/141/16
Ear discomfortEar and labyrinth disorders0/170/160/160/170/161/160/141/16
HypoacusisEar and labyrinth disorders0/170/160/160/170/161/160/141/16
DyspepsiaGastrointestinal disorders0/170/160/160/170/161/160/141/16
Muscular weaknessMusculoskeletal and connective tissue disorders0/170/160/160/170/161/160/141/16

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Cohort 1 (DC-806 200 mg / Itraconazole)Cohort 2 (DC-806 800 mg / Carbamazepine)Total
Mean28.2 ± 8.5537.4 ± 11.4132.7 ± 10.94
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 (DC-806 200 mg / Itraconazole)Cohort 2 (DC-806 800 mg / Carbamazepine)Total
Female022
Male171431
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 (DC-806 200 mg / Itraconazole)Cohort 2 (DC-806 800 mg / Carbamazepine)Total
Hispanic or Latino369
Not Hispanic or Latino13922
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 (DC-806 200 mg / Itraconazole)Cohort 2 (DC-806 800 mg / Carbamazepine)Total
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander101
Black or African American325
White111223
More than one race123
Unknown or Not Reported000
08

Study locations

1 site
  • ICON Phase I Clinic
    Salt Lake City, Utah 84124, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Sep 2023, 1 month.

Results were first posted in Oct 2026, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2023
First posted
Aug 16, 2023
StartActual
Aug 8, 2023
Primary completionActual
Sep 20, 2023
CompletionActual
Sep 20, 2023
Results first posted
Oct 19, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 19, 2026
Interventions
Arms added: Cohort 1 (DC-806 200 mg / Itraconazole)·Cohort 2 (DC-806 800 mg / Carbamazepine); arms removed: Cohort 1·Cohort 2
Oct 19, 2026
Primary outcomes
6 edited
What changed in the outcomes
  • EditedCohort 1: Maximum Observed Plasma ConcentrationsConcentration (Cmax) of DC-806Time frame: Day 1 to Day 11 → Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 7 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
  • EditedCohort 2: Maximum Observed Plasma Concentration (Cmax) of DC-806Time frame: Day 1 to Day 25 → Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 18 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
  • EditedCohort 1: Area Under the Plasma Concentration-timeTime Curve UpFrom Time Zero to Time tthe Last Measurable Concentration (AUC0-t) of DC-806Time frame: Day 1 to Day 11 → Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 7 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
  • EditedCohort 1: Area Under the Plasma Concentration-time Curve fromFrom Time 0 Extrapolated to Infinity (AUC0-inf) of DC-806Time frame: Day 1 to Day 11 → Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 7 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
  • EditedCohort 2: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of DC-806Time frame: Day 1 to Day 25 → Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 18 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
  • ChangedBefore Cohort 2: AUC0-t of DC-806Now Cohort 2: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of DC-806Time frame: Day 1 to Day 25 → Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 18 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
Oct 19, 2026
Documents
Secondary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Cohorts 1 and 2: Number of Participants who Experience an Adverse EventNow Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to a maximum of 31 days → Cohort 1: Day 1 up to Day 23; Cohort 2: Day 1 up to Day 33.
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Results posted
    Primary outcomes 6 edited
    What changed in the outcomes
    • EditedCohort 1: Maximum Observed Plasma ConcentrationsConcentration (Cmax) of DC-806Time frame: Day 1 to Day 11 → Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 7 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
    • EditedCohort 2: Maximum Observed Plasma Concentration (Cmax) of DC-806Time frame: Day 1 to Day 25 → Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 18 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
    • EditedCohort 1: Area Under the Plasma Concentration-timeTime Curve UpFrom Time Zero to Time tthe Last Measurable Concentration (AUC0-t) of DC-806Time frame: Day 1 to Day 11 → Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 7 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
    • EditedCohort 1: Area Under the Plasma Concentration-time Curve fromFrom Time 0 Extrapolated to Infinity (AUC0-inf) of DC-806Time frame: Day 1 to Day 11 → Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 7 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
    • EditedCohort 2: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of DC-806Time frame: Day 1 to Day 25 → Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 18 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
    • ChangedBefore Cohort 2: AUC0-t of DC-806Now Cohort 2: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of DC-806Time frame: Day 1 to Day 25 → Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 18 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Cohorts 1 and 2: Number of Participants who Experience an Adverse EventNow Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to a maximum of 31 days → Cohort 1: Day 1 up to Day 23; Cohort 2: Day 1 up to Day 33.
    Interventions Arms added: Cohort 1 (DC-806 200 mg / Itraconazole)·Cohort 2 (DC-806 800 mg / Carbamazepine); arms removed: Cohort 1·Cohort 2
    + 4 other changes: index terms, identifiers, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05994807
Responsible party
Sponsor
First posted
Aug 16, 2023
Start date
Aug 8, 2023
Primary completion
Sep 20, 2023
Completion
Sep 20, 2023
Results posted
Oct 19, 2026
Last update
Oct 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DC-806

Start the discussion